Patents by Inventor Hartmut Ehrlich

Hartmut Ehrlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10329583
    Abstract: The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 25, 2019
    Assignee: OLOGY BIOSERVICES INC.
    Inventors: Falko-Günter Falkner, Birgit Schafer, P Noel Barrett, Thomas R. Kreil, Hartmut Ehrlich, Annett Hessel
  • Publication number: 20190134147
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 9, 2019
    Applicants: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Patent number: 10201586
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 12, 2019
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Publication number: 20180291087
    Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.
    Type: Application
    Filed: October 30, 2017
    Publication date: October 11, 2018
    Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
  • Publication number: 20180280501
    Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with glucocorticoids, in the treatment of glucocorticoid receptive diseases.
    Type: Application
    Filed: November 1, 2017
    Publication date: October 4, 2018
    Inventors: Randolf Kerschbaumer, Dirk Voelkel, Friedrich Scheiflinger, Hartmut Ehrlich
  • Publication number: 20180072784
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
    Type: Application
    Filed: August 18, 2017
    Publication date: March 15, 2018
    Applicants: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael DOCKAL, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
  • Patent number: 9884105
    Abstract: The present invention relates, in general, to materials and methods for production of an improved vaccine against influenza virus, wherein the vaccine comprises a reassortant virus having a hemagglutinin gene and a neuraminidase gene from the same influenza A virus subtype or influenza B strain of virus and internal genes from a different influenza A virus subtype or influenza B strain of virus. In one aspect, the HA and NA genes and the internal genes are from a highly pathogenic H5N1 strain of influenza A.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: February 6, 2018
    Assignee: OLOGY BIOSERVICES, INC.
    Inventors: Otfried Kistner, Falko-Guenter Falkner, Hartmut Ehrlich, Noel Barrett
  • Patent number: 9834593
    Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: December 5, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
  • Patent number: 9777051
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 3, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
  • Publication number: 20170267743
    Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
    Type: Application
    Filed: November 2, 2016
    Publication date: September 21, 2017
    Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
  • Publication number: 20170157198
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
    Type: Application
    Filed: December 9, 2016
    Publication date: June 8, 2017
    Applicants: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Publication number: 20170121735
    Abstract: The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses.
    Type: Application
    Filed: October 7, 2016
    Publication date: May 4, 2017
    Inventors: Falko-Günter FALKNER, Birgit SCHAFER, P. Noel BARRETT, Thomas R. KREIL, Hartmut EHRLICH, Annett HESSEL
  • Publication number: 20170049885
    Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with cancer therapeutics, i.e. chemotherapeutics, in the treatment of cancer.
    Type: Application
    Filed: June 6, 2016
    Publication date: February 23, 2017
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Hartmut Ehrlich
  • Patent number: 9556230
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: January 31, 2017
    Assignees: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Patent number: 9512198
    Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: December 6, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
  • Patent number: 9463237
    Abstract: The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: October 11, 2016
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Falko-Günter Falkner, Birgit Schafer, P. Noel Barrett, Thomas R. Kreil, Hartmut Ehrlich, Annett Hessel
  • Publication number: 20150250873
    Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with glucocorticoids, in the treatment of glycocorticoid receptive diseases.
    Type: Application
    Filed: April 16, 2013
    Publication date: September 10, 2015
    Inventors: Randolf Kerschbaumer, Dirk Voelkel, Friedrich Scheiflinger, Hartmut Ehrlich
  • Publication number: 20150232514
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Application
    Filed: April 2, 2015
    Publication date: August 20, 2015
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Publication number: 20150232536
    Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.
    Type: Application
    Filed: February 18, 2015
    Publication date: August 20, 2015
    Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
  • Publication number: 20150203567
    Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 23, 2015
    Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich